Theraclion: 1st Echotherapy Centers for Benign Thyroid Nodules in Italy

Regulatory News:

THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that the A.S.L. 6 di Livorno, a public hospital based in Tuscany, Italy, has signed a commercial agreement for use of the Echopulse® system. The center will utilize Echopulse for the treatment of benign thyroid nodules. Theraclion also announces the start of a clinical research program within the department of Professor Enrico Papini at the hospital Regina Apostolorum, Rome.

1^st commercial agreement signed in Italy

The A.S.L. 6 di Livorno acquired a Theraclion echotherapy system and will be offering echotherapy for benign thyroid nodules to their patients. The department of Malattie Endocrine e Metaboliche of A.S.L. 6 di Livorno is internationally renowned for its experience in minimally invasive treatments of thyroid nodules. It was the first center in Tuscany and one of the first centers in Italy to perform thyroid nodule laser treatments. Now it will be the first center in Italy to offer treatments for benign thyroid nodules with an echotherapy system of Theraclion. Dr. Daniele Barbaro, head of the department of Malattie Endocrine e Metaboliche of A.S.L. 6 di Livorno and leader of the thyroid program, has substantial experience deploying novel minimally invasive treatments.

"I personally believe that echotherapy is a step forward from what we have performed in previous years,” says Dr. Barbaro "Our extensive experience in minimally invasive treatments will be crucial in this new non-invasive approach, a real alternative for patients who are unable or don’t wish to undergo surgery.”

Important clinical study to start at the renowned endocrinology center of Rome

Theraclion also announces that a clinical research collaboration agreement has been signed with the hospital Regina Apostolorum (Albano Laziale, Rome) and the department of Professor Enrico Papini and Doctor Giancarlo Bizzarri, world-leading specialists in endocrinology. Professor Enrico Papini is internationally known as a pioneer in thermoablation methods for the treatment of thyroid diseases. He is co-author of the American, Italian and European Endocrinology Associations’ guidelines for clinical practice for the diagnosis and managements of thyroid nodules and numerous scientific articles.

"With more than 6 million people who suffer from thyroid disease and more than 40,000 thyroidectomies performed every year, Italy is one of the biggest markets within Europe for Theraclion,” says Giuliano Laghi, VP Business Development Southern Europe. ”Clinical adoption might be much quicker in Italy than in other countries as other thermoablative methods have already paved the way in Italy and patient pathways and reimbursements for those methods exist.”

"Following the changes we made to our direct sales strategy last year, we are pleased to add two great Italian sites to our network of Echopulse users. One site will be an anchor commercial partner and given Pr. Papini’s thought leadership in thermal ablation, the other site will augment out technology’s clinical validation,” adds David Caumartin, CEO of Theraclion.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629006068/en/